The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Innophos Holdings's revenues will increase 6.4% and EPS will drop 0.0%.
The average estimate for revenue is $227.8 million. On the bottom line, the average EPS estimate is $0.81.
Last quarter, Innophos Holdings booked revenue of $214.4 million. GAAP reported sales were 6.1% lower than the prior-year quarter's $228.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.60. GAAP EPS of $0.55 for Q1 were 55% lower than the prior-year quarter's $1.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 17.6%, 690 basis points worse than the prior-year quarter. Operating margin was 8.7%, 800 basis points worse than the prior-year quarter. Net margin was 5.8%, 630 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $903.2 million. The average EPS estimate is $3.22.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 784 members out of 807 rating the stock outperform, and 23 members rating it underperform. Among 243 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 238 give Innophos Holdings a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Innophos Holdings is outperform, with an average price target of $58.25.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Innophos Holdings. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Innophos Holdings to My Watchlist.